According to a recent LinkedIn post from Parallel Fluidics, the company is promoting on-site demonstrations of its LNP Screening Array for local Boston-area biopharma labs. The post indicates the system can be integrated with a customer’s existing liquid handler to automate lipid nanoparticle formulation workflows.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The post also notes that Parallel Fluidics intends to provide “Starter Arrays” so prospective users can run initial campaigns at no cost. For investors, this hands-on, locality-focused demo strategy may help accelerate customer adoption, deepen engagement with Boston’s dense biotech cluster, and support recurring revenue potential tied to consumables and ongoing LNP development programs.